MoonLake Immunotherapeutics Income Statement
MLTX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| SG&A Expense | $42.0M | $30.3M | $22.3M | $23.0M | $18.0M | $105.8K |
| R&D Expense | $202.9M | $112.8M | $31.8M | $42.0M | $35.5M | - |
| Operating Income | -$244.8M | -$143.1M | -$54.1M | -$65.1M | -$53.6M | -$105.8K |
| Income Tax | $611.0K | $282.0K | $94.0K | $36.4K | $4.8K | - |
| Net Income | -$227.3M | -$118.9M | -$36.0M | -$50.0M | -$53.6M | -$90.8K |
| EPS (Basic) | -$3.53 | -$1.89 | -$0.73 | -$1.70 | -$6.84 | - |
| EPS (Diluted) | -$3.53 | -$1.89 | -$0.73 | -$1.70 | -$6.84 | - |
| Shares Outstanding | 64.5M | 62.9M | 49.1M | 29.4M | 7.8M | 6.2M |